Ribon Therapeutics Stock

ribontx.comHealthcareFounded: 2015Funding to Date: $108.5MM

Ribon is a clinical-stage biotechnology company dedicated to the discovery and development of first-in-class small molecule inhibitors to block the fundamental ability of cancer cells to survive under stress.

Register for Details

For more details on financing and valuation for Ribon Therapeutics, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for Ribon Therapeutics.

Register Today


Management Team

Paul Chang Ph.D
Scientific Co-Founder
Kevin Kuntz Ph.D
Vice President, Molecular Discovery
David Cordo
Chief Financial Officer
Victoria Richon Ph.D
President, Chief Executive Officer & Board Member
W. Kraus Ph.D
Scientific Co-Founder
Sudha Parasuraman MD
Chief Medical Officer
Tim Mitchison Ph.D
Scientific Co-Founder
Heike Keilhack Ph.D
Vice President of Biological Sciences
Edward Stewart
Chief Business Officer

Board Members

James Audia Ph.D
Anja K├Ânig Ph.D
Novartis Venture Fund
Jonathan Root MD
US Venture Partners
William Harrington MD
Osage Venture Partners
Cameron Wheeler Ph.D
Deerfield Management
Laurence Lasky Ph.D
The Column Group
Marian Nakada
Peter Svennilson
The Column Group

Other companies like Ribon Therapeutics in the Healthcare sector

Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation